Trial | NCT02865005  Report issue

Title

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Dapsone 5% Gel (SEEGPharm SA) to Aczone® and Both Active Treatments Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    dapsone ...

  • Study Participants

    2361
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris for 84 days in male and female subjects age 12-40.
Study Started
Feb 29
2016
Primary Completion
Nov 30
2016
Study Completion
Dec 31
2016
Last Update
Dec 20
2016
Estimate

Drug Dapsone 5.0% Gel (SEEGPharm)

Topical Gel

  • Other names: Experimental Arm

Other Placebo

Topical Gel

  • Other names: Placebo Comparator

Drug Dapsone 5.0% Gel (Allergan)

Topical Gel

  • Other names: Active Comparator

Dapsone 5.0% Gel (Allergan) Active Comparator

Dapsone 5.0% Gel applied twice daily for 84 days

Dapsone 5.0% Gel (SEEGPharm) Experimental

Dapsone 5.0% Gel applied twice daily for 84 days

Placebo Placebo Comparator

Vehicle of Experimental Gel applied twice daily for 84 days

Criteria 

Inclusion Criteria:

Healthy male or non-pregnant females aged ≥ 12 and ≤ 40 years of age with a clinical diagnosis of acne vulgaris.
Informed Consent/Assent: For subjects 12 to 17 years of age inclusive must have provided Institutional Review Board (IRB) approved written assent that must be accompanied by an IRB approved written consent from the subject's legally acceptable representatives (i.e., parent or guardian). In addition, all subjects or their legally acceptable representatives must sign a Health Insurance Portability and Accountability Act (HIPAA) authorization.
On the face, subjects must have ≥ 20 inflammatory lesions (i.e., papules and pustules), AND ≥ 25 non-inflammatory lesions (open and closed comedones) AND ≤ 2 nodulocystic lesions (i.e., nodules and cysts). For the purposes of study treatment and evaluation, all lesions on the face should be counted, including those on the nose. Subjects may have acne lesions on other areas of the body (e.g., back, chest, and arms) which should be excluded from the count, treatment and the IGA evaluation.
Subjects must have an acne severity grade of 3 or 4 per the IGA
Subjects must be willing to refrain from using all other topical acne medications or antibiotics during the 12-week treatment period other than the study drug.

Exclusion Criteria:

Prior or current concomitant therapies that would interfere with assessments in the study.
Prior or current concomitant therapies skin conditions that would interfere with assessments in the study.
Prior, current or planned procedures that would interfere with assessments in the study.
Current or planned activities that would interfere with assessment in the study.
Subjects who have a Baseline local skin site reaction score of 3 [severe (marked/intense)] for any signs and/or symptoms of irritation as scored using the local skin site reaction scores.
No Results Posted